Testing effectiveness (Phase 2)Looking for participantsNCT05943379What this trial is testingRC48-ADC in Combination With Gemcitabine in High Risk NMIBC SubjectsWho this might be right forNMIBC RemeGen Co., Ltd. 85
Testing effectiveness (Phase 2)Study completedNCT01259063What this trial is testingRAD001 and Intravesical Gemcitabine in BCG-Refractory Primary or Secondary Carcinoma In Situ of the BladderWho this might be right forBladder Cancer Memorial Sloan Kettering Cancer Center 33
Not applicableUnknownNCT06374914What this trial is testingSequential Intravesical Gemcitabine and Docetaxel for Rescue Therapy in BCG Unresponsive Non-muscle Invasive Bladder Cancer PatientsWho this might be right forBladder CancerBCGGemcitabine+2 more Dokuz Eylul University 120
Large-scale testing (Phase 3)Study completedNCT00006034What this trial is testingKeyhole Limpet Hemocyanin Compared With Doxorubicin in Treating Patients With Bladder CancerWho this might be right forBladder Cancer Intracel
Testing effectiveness (Phase 2)WithdrawnNCT04040725What this trial is testingRogaratinib for BCG Refractory High Risk Non-Muscle Invasive Bladder Cancer With FGFR1/2 OverexpressionWho this might be right forBladder Cancer Dana-Farber Cancer Institute
Testing effectiveness (Phase 2)Looking for participantsNCT07283835What this trial is testingStudy of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-GuerinWho this might be right forNon Muscle Invasive Bladder CancerHigh-grade Ta/ T1 Papillary Disease Bladder Cancer Lepu Biopharma Co., Ltd. 16
Testing effectiveness (Phase 2)Active Not RecruitingNCT04164082What this trial is testingTesting the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder CancerWho this might be right forBladder Flat Urothelial Carcinoma In SituNon-Muscle Invasive Bladder Urothelial CarcinomaStage 0a Bladder Cancer AJCC v8+2 more National Cancer Institute (NCI) 161
Testing effectiveness (Phase 2)Ended earlyNCT03719300What this trial is testingCodex: Study of Inodiftagene Vixteplasmid (BC-819) in Unresponsive NMIBCWho this might be right forNon-muscle Invasive Bladder Cancer (NMIBC) Anchiano Therapeutics Israel Ltd. 32
Testing effectiveness (Phase 2)Looking for participantsNCT06972615What this trial is testingIntravesical Chemotherapy in Combination With Systemic Pembrolizumab in NMIBC Unresponsive or Exposed to BCG TherapyWho this might be right forNon Muscle Invasive Bladder Cancer BLATAM 37
Large-scale testing (Phase 3)Active Not RecruitingNCT04165317What this trial is testingSasanlimab in People With Non-muscle Invasive Bladder CancerWho this might be right forNon-muscle Invasive Bladder Cancer Pfizer 1,068
Testing effectiveness (Phase 2)Looking for participantsNCT04106115What this trial is testingDURvalumab in Combination With S-488210/S-488211 vAccine in Non-muscle Invasive Bladder CancErWho this might be right forBladder Cancer University College, London 52
Early research (Phase 1)Study completedNCT00694798What this trial is testingStudy of Mycobacterium w in BCG Refractory Superficial Transitional Cell Carcinoma of BladderWho this might be right forBladder Cancer Cadila Pharnmaceuticals 22
Testing effectiveness (Phase 2)Active Not RecruitingNCT04640623What this trial is testingTAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical CystectomyWho this might be right forUrinary Bladder Neoplasms Janssen Research & Development, LLC 220
Early research (Phase 1)WithdrawnNCT00014287What this trial is testingGemcitabine in Treating Patients With Recurrent or Refractory Bladder CancerWho this might be right forBladder Cancer University of Pittsburgh
Testing effectiveness (Phase 2)Study completedNCT02844816What this trial is testingAtezolizumab in Treating Patients With Recurrent BCG-Unresponsive Non-muscle Invasive Bladder CancerWho this might be right forRecurrent Bladder Urothelial CarcinomaStage 0a Bladder Urothelial Carcinoma AJCC v6 and v7Stage 0is Bladder Urothelial Carcinoma AJCC v6 and v7+1 more National Cancer Institute (NCI) 172
Testing effectiveness (Phase 2)Ended earlyNCT02625961What this trial is testingStudy of Pembrolizumab (MK-3475) and Pembrolizumab With Other Investigational Agents in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/KEYNOTE-057)Who this might be right forBladder Cancer Merck Sharp & Dohme LLC 296
Large-scale testing (Phase 3)Looking for participantsNCT07424287What this trial is testingIntravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBCWho this might be right forNMIBC Suzhou Suncadia Biopharmaceuticals Co., Ltd. 236
Early research (Phase 1)Study completedNCT02808143What this trial is testingPembrolizumab and BCG Solution in Treating Patients With Recurrent Non-Muscle-Invasive Bladder CancerWho this might be right forRecurrent Bladder CarcinomaStage 0a Bladder Urothelial CarcinomaStage 0is Bladder Urothelial Carcinoma+1 more Northwestern University 9
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06255964What this trial is testingIAP0971 in Combination With Bacillus Calmette Guerin in High Risk Non-muscular Invasive Bladder CancerWho this might be right forBladder Cancer SUNHO（China）BioPharmaceutical CO., Ltd. 236
Testing effectiveness (Phase 2)Active Not RecruitingNCT03317158What this trial is testingModern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the BladderWho this might be right forUrothelial CarcinomaBladder Cancer Noah Hahn, M.D. 186